Mining company Rio Tinto issued an apology

an 8mm by 6mm silver capsule, no bigger than a coin, believed to be lost somewhere along a stretch of vast desert highway in Australia’s biggest state. […] Authorities believe the capsule, which emits both gamma and beta rays, fell off the back of a truck […] creating a radioactive health risk for anyone who comes across it for potentially the next 300 years […] Mining company Rio Tinto issued an apology [more]

‘Doppelganger murder’: German prosecutors claim woman killed lookalike to fake death

Through its savvy but legal exploitation of the U.S. patent system, Humira’s manufacturer, AbbVie, blocked competitors from entering the market. […] the drug’s price kept rising. […] Humira is the most lucrative franchise in pharmaceutical history. Next week […] the knockoff drug that regulators authorized more than six years ago, Amgen’s Amjevita, will come to market […] nine more Humira competitors will follow this year […] Prices are likely to tumble. The reason that it has taken so long to get to this point is a case study in how drug companies artificially prop up prices on their best-selling drugs. AbbVie orchestrated the delay by building a formidable wall of intellectual property protection and suing would-be competitors before settling with them to delay their product launches until this year. The strategy has been a gold mine for AbbVie, at the expense of patients and taxpayers. […] For example, an early Humira patent, which expired in 2016, claimed that the drug could treat a condition known as ankylosing spondylitis, a type of arthritis that causes inflammation in the joints, among other diseases. In 2014, AbbVie applied for another patent for a method of treating ankylosing spondylitis with a specific dosing of 40 milligrams of Humira. The application was approved, adding 11 years of patent protection beyond 2016. […] One analysis found that Medicare, which in 2020 covered the cost of Humira for 42,000 patients, spent $2.2 billion more on the drug from 2016 to 2019 than it would have if competitors had been allowed to start selling their drugs promptly. […] “AbbVie and Humira showed other companies what it was possible to do.”

Usage of Children’s Makeup and Body Products in the United States and Implications for Childhood Environmental Exposures

Study finds that UV-emitting nail polish dryers damage DNA and cause mutations in cells

Homeopathy suggests treating genetic diseases with tiny doses of the patient’s own DNA “It is important to reiterate that this is a theoretical hypothesis and without scientific evidence so far”

Delta (1 – 4 Hz) EEG/MEG activity is generally indicative of loss of consciousness and cortical down states, particularly when it is diffuse and high amplitude. Remarkably, however, drug challenge studies of several diverse classes of pharmacological agents—including antiepileptics, GABA-B-ergics, anticholinergics, and psychedelic tryptamines—demonstrate that participants appear to be neurophysiologically “down” (EEG activity resembling cortical down states) even when they are not psychologically “out” (unconscious). Of those substances that are safe to use in healthy volunteers, some may be highly valuable research tools for investigating which neural activity patterns are sufficient for consciousness or its absence.

Consider Michel de Montaigne, who in 1571, fed up with his job as a magistrate in the city of Bordeaux, quit at the age of 38. Retreating to his library, he inscribed his reason on the wall of his study. “Weary of the servitude of the courts,” Mr. Montaigne declared, “I am determined to retire in order to spend what little remains of my life, now more than half run out … consecrated to my freedom, tranquillity, and leisure.” He went on to invent an entirely new kind of writing — the essay — by which he launched an extraordinary experiment in self-examination. Yet he experimented lazily. “I have to solicit it nonchalantly,” he wrote about his memory. “What I do easily and naturally I can no longer do if I order myself to do it by strict and express command,” he wrote. For the man who transformed our way of reading and writing, he was seriously unserious. “If I encounter difficulties in reading, I do not gnaw my nails over them; I leave them there.” He added: “I do nothing without gaiety.” [NY Times]

We recommend avoiding general and often dehumanizing “the” labels such as the poor, the mentally ill, the French, the disabled, the college-educated. Instead, use wording such as people with mental illnesses. And use these descriptions only when clearly relevant. [@APStylebook]

Who will compete with ChatGPT? Meet the contenders Interior design mockups and virtual staging by AI

Channa Horwitz, Sonakinatography I Movement #III for Multi-Media, 1969

Incels are transitioning to women for sex. It’s called Transmaxxing. They have a manual.